Morgan Stanley Issues Positive Forecast for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price increased by Morgan Stanley from $30.00 to $32.00 in a report released on Friday morning,Benzinga reports. Morgan Stanley currently has an underweight rating on the stock. Other analysts also recently issued reports about the company. Barclays increased their price objective on CRISPR Therapeutics from $55.00 […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price increased by Morgan Stanley from $30.00 to $32.00 in a report released on Friday morning,Benzinga reports. Morgan Stanley currently has an underweight rating on the stock. Other analysts also recently issued reports about the company. Barclays increased their price objective on CRISPR Therapeutics from $55.00 […]
